The introduction of FILKRI (filgrastim-laha) marks a strategic expansion for the Raleigh-based company, which aims to bring 20 biosimilar products to the U.S. market by 2030. By manufacturing the drug end-to-end through its parent firm, Intas Pharmaceuticals, Accord BioPharma intends to offer a stable supply chain for oncology supportive care. The product joins an existing portfolio that includes the long-acting treatment UDENYCA, providing physicians with both short- and long-acting G-CSF options to manage patients undergoing chemotherapy or those exposed to myelosuppressive radiation.
Accord BioPharma Launches FILKRI Biosimilar for Neutropenia Management
Accord BioPharma has launched FILKRI, a new biosimilar to Neupogen, in the United States. Approved by the FDA earlier this year, the treatment for neutropenia arrives with a permanent Q-code, a move intended to streamline billing and reimbursement processes for healthcare providers across the country from the first day of availability.
Beyond clinical utility, the company is prioritizing accessibility. Through the AccordCares program, the manufacturer is providing benefits investigation and co-pay assistance to mitigate financial barriers for patients. The assignment of permanent Q-code Q5172 by the Centers for Medicare & Medicaid Services is designed to simplify the administrative burden for hospitals and clinics, ensuring that reimbursement protocols are consistent across all care settings. This launch reinforces the firm’s broader strategy of challenging established biologics with high-quality, cost-effective alternatives.
Comments (0)
No comments yet. Be the first!